These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 27087351)

  • 21. [When and how to treat a central precocious puberty?].
    Carel JC; Linglart A; Roger M; Lalhou N; Chaussain JL
    Arch Pediatr; 2002 May; 9 Suppl 2():237s-239s. PubMed ID: 12108279
    [No Abstract]   [Full Text] [Related]  

  • 22. Optic glioma and precocious puberty in a girl with neurofibromatosis type 1 carrying an R681X mutation of NF1: case report and review of the literature.
    Kocova M; Kochova E; Sukarova-Angelovska E
    BMC Endocr Disord; 2015 Dec; 15():82. PubMed ID: 26666878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of Systemic Hypersensitivity Reactions to Gonadotropin-Releasing Hormone Analogues during Treatment of Central Precocious Puberty.
    Kirkgoz T; Karakoc-Aydiner E; Bugrul F; Yavas Abali Z; Helvacioglu D; Kiykim A; Bilgic Eltan S; Aruci Kasap N; Baris S; Ozen A; Guran T; Bereket A; Turan S
    Horm Res Paediatr; 2020; 93(1):66-72. PubMed ID: 31972562
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of an ultrasensitive recombinant cell bioassay to determine estrogen levels in girls with precocious puberty treated with a luteinizing hormone-releasing hormone agonist.
    Klein KO; Baron J; Barnes KM; Pescovitz OH; Cutler GB
    J Clin Endocrinol Metab; 1998 Jul; 83(7):2387-9. PubMed ID: 9661615
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment?
    Léger J; Reynaud R; Czernichow P
    J Pediatr; 2000 Dec; 137(6):819-25. PubMed ID: 11113839
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty.
    Carel JC; Roger M; Ispas S; Tondu F; Lahlou N; Blumberg J; Chaussain JL
    J Clin Endocrinol Metab; 1999 Jun; 84(6):1973-8. PubMed ID: 10372696
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gonadotropin-releasing hormone analogues in the management of precocious puberty.
    Spiliotis BE
    Ann N Y Acad Sci; 2000; 900():429-34. PubMed ID: 10818433
    [No Abstract]   [Full Text] [Related]  

  • 29. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
    Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
    J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sexual precocity in boys: accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height.
    Lazar L; Pertzelan A; Weintrob N; Phillip M; Kauli R
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4127-32. PubMed ID: 11549638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty.
    Manasco PK; Pescovitz OH; Feuillan PP; Hench KD; Barnes KM; Jones J; Hill SC; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1988 Aug; 67(2):368-72. PubMed ID: 3292562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
    Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
    Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of efficacy of fadrozole in treating precocious puberty in girls with the McCune-Albright syndrome.
    Nunez SB; Calis K; Cutler GB; Jones J; Feuillan PP
    J Clin Endocrinol Metab; 2003 Dec; 88(12):5730-3. PubMed ID: 14671160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Precocious puberty in a patient with indicanuria.
    Büyükgebiz B; Uğuz A; Böber E; Büyükgebiz A
    J Pediatr Endocrinol Metab; 1999; 12(4):561-3. PubMed ID: 10417974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variable response to a long-acting agonist of luteinizing hormone-releasing hormone in girls with McCune-Albright syndrome.
    Foster CM; Comite F; Pescovitz OH; Ross JL; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1984 Oct; 59(4):801-5. PubMed ID: 6434582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anaphylaxis to gonadorelin acetate in a girl with central precocious puberty.
    Akın O; Yavuz ST; Hacıhamdioğlu B; Sarı E; Gürsel O; Yeşilkaya E
    J Pediatr Endocrinol Metab; 2015 Nov; 28(11-12):1387-9. PubMed ID: 26197466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Precocious puberty in Sanfilippo IIIA disease: diagnosis and follow-up of two new cases.
    Concolino D; Muzzi G; Pisaturo L; Piccirillo A; Di Natale P; Strisciuglio P
    Eur J Med Genet; 2008; 51(5):466-71. PubMed ID: 18586597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autoimmune thyroiditis and diabetes mellitus type 1 after long-term gonadotropin-releasing hormone agonist treatment for central precocious puberty: evolution or coincidence?
    Krstevska-Konstantinova M; Jancevska A; Gucev Z
    J Pediatr Endocrinol Metab; 2010 Apr; 23(4):403-6. PubMed ID: 20583547
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic use of pituitary desensitization with a long-acting lhrh agonist: a potential new treatment for idiopathic precocious puberty.
    Crowley WF; Comite F; Vale W; Rivier J; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1981 Feb; 52(2):370-2. PubMed ID: 6780592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Somatomedin-C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist.
    Harris DA; Van Vliet G; Egli CA; Grumbach MM; Kaplan SL; Styne DM; Vainsel M
    J Clin Endocrinol Metab; 1985 Jul; 61(1):152-9. PubMed ID: 3889035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.